Nancy Jo Wesensten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nancy Jo Wesensten has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Thomas J. Balkin
Behavioral Biology Branch Center for Military Psychiatry and Neuroscience Walter Reed Army Institute of Research Silver Spring MD USA
5 shared publications- Thomas J. Balkin
Department of Behavioral Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
4 shared publications - Gregory Belenky
Division of Neuropsychiatry, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA
2 shared publications Tracy L. Rupp
Behavioral Biology Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
2 shared publicationsBrian M. Kleiner
1 shared publicationDaniel P Redmond
1 shared publication
Latest Publications
- 28 May 2015
- Published by SAGE Publications in Reviews of Human Factors and Ergonomics
- Vol. 10 (1) , 115-137
Countermeasures for Mitigating Fatigue in Motor Vehicle Operators
Sleep debt and time of day/night (circadian rhythm) exert substantial effects on commercial motor vehicle (CMV) operator (e.g. truck and bus/motor coach, railroad engineer, aviation pilot) performance—and, therefore, safety. In this chapter, the influence of sleep debt and circadian effects on operator performance are described. Efficacy of various countermeasures is reviewed, and the influence of individual operator traits (genetic factors) is briefly discussed. It is concluded that sleep (napping) remains the best strategy for restoring and maintaining CMV operator neurobehavioral performance. Results from ongoing research will lead to occupation-specific and individualized strategies for managing sleepiness and fatigue in operational environments.
- 28 May 2015
- Published by SAGE Publications in Reviews of Human Factors and Ergonomics
- Vol. 10 (1) , 115-137
Countermeasures for Mitigating Fatigue in Motor Vehicle Operators
Sleep debt and time of day/night (circadian rhythm) exert substantial effects on commercial motor vehicle (CMV) operator (e.g. truck and bus/motor coach, railroad engineer, aviation pilot) performance—and, therefore, safety. In this chapter, the influence of sleep debt and circadian effects on operator performance are described. Efficacy of various countermeasures is reviewed, and the influence of individual operator traits (genetic factors) is briefly discussed. It is concluded that sleep (napping) remains the best strategy for restoring and maintaining CMV operator neurobehavioral performance. Results from ongoing research will lead to occupation-specific and individualized strategies for managing sleepiness and fatigue in operational environments.
- 23 October 2013
- p. 109-18
The challenge of sleep management in military operations.
It has long been known that short-term (days) insufficient sleep causes decrements in mental effectiveness that put individuals at increased risk of committing errors and causing accidents. More recently, it has been discovered that chronic poor sleep (over years) is associated with a variety of negative health outcomes (metabolic syndrome, obesity, degraded behavioral health). Implementing an effective sleep health program is, therefore, in the best interests of active duty personnel and their families both in the short- and long-term. Like managing physical activity or nutrition, effectively managing sleep health comes with its unique set of challenges arising from the fact that individuals who routinely do not obtain sufficient sleep are generally desensitized to feeling sleepy and are poor at judging their own performance capabilities--and individuals cannot be compelled to sleep. For these reasons, an optimally effective sleep health program requires 3 components: (1) a rigorous, evidence-based sleep education component to impart actionable knowledge about optimal sleep amounts, healthy sleep behaviors, the known benefits of sleep, the short- and long-term consequences of insufficient sleep, and to dispel myths about sleep; (2) a nonintrusive device that objectively and accurately measures sleep to empower the individual to track his/her own sleep/wake habits; and (3) a meaningful, actionable metric reflecting sleep/wake impact on daily effectiveness so that the individual sees the consequences of his/her sleep behavior and, therefore, can make informed sleep health choices.
- 23 October 2013
- p. 109-18
The challenge of sleep management in military operations.
It has long been known that short-term (days) insufficient sleep causes decrements in mental effectiveness that put individuals at increased risk of committing errors and causing accidents. More recently, it has been discovered that chronic poor sleep (over years) is associated with a variety of negative health outcomes (metabolic syndrome, obesity, degraded behavioral health). Implementing an effective sleep health program is, therefore, in the best interests of active duty personnel and their families both in the short- and long-term. Like managing physical activity or nutrition, effectively managing sleep health comes with its unique set of challenges arising from the fact that individuals who routinely do not obtain sufficient sleep are generally desensitized to feeling sleepy and are poor at judging their own performance capabilities--and individuals cannot be compelled to sleep. For these reasons, an optimally effective sleep health program requires 3 components: (1) a rigorous, evidence-based sleep education component to impart actionable knowledge about optimal sleep amounts, healthy sleep behaviors, the known benefits of sleep, the short- and long-term consequences of insufficient sleep, and to dispel myths about sleep; (2) a nonintrusive device that objectively and accurately measures sleep to empower the individual to track his/her own sleep/wake habits; and (3) a meaningful, actionable metric reflecting sleep/wake impact on daily effectiveness so that the individual sees the consequences of his/her sleep behavior and, therefore, can make informed sleep health choices.
- Open Access
- 21 November 2012
- Published by Wiley in Journal of Sleep Research
- Vol. 22 (2) , 160-165
PER3 and ADORA2A polymorphisms impact neurobehavioral performance during sleep restriction
Summary: The objective of the study was to determine whether ADORA2A or PER3 polymorphisms contribute to individual responsivity to sleep restriction. Nineteen healthy adults (ages 18–39, 11 males, 8 females) underwent sleep restriction (SR) which consisted of seven nights of 3 h time in bed (TIB) (04:00–07:00). SR was preceded by seven in‐laboratory nights of 10 h TIB (21:00–07:00) and followed by three nights of 8 h TIB (23:00–07:00). Volunteers underwent psychomotor vigilance, objective alertness, and subjective sleepiness assessments throughout. Volunteers were genotyped for the PER3 VNTR polymorphism (PER34/4 n = 7; PER34/5 n = 10; PER35/5 n = 2) and the ADORA2A c.1083T>C polymorphism, (ADORA2AC/T n = 9; ADORA2AT/T n = 9; ADORA2AC/C n = 1) using polymerase chain reaction (PCR). Separate mixed‐model anovas were used to assess contributions of ADORA2A and PER3 polymorphisms. Results showed that PER34/4 and ADORA2AC/T individuals expressed greater behavioral resiliency to SR compared to PER4/5and ADORA2AT/T individuals. Our findings contrast with previously reported non‐significant effects for the PER3 polymorphism under a less challenging sleep restriction regimen (4 h TIB per night for five nights). We conclude that PER3 and ADORA2A polymorphisms become more behaviorally salient with increasing severity and/or duration of sleep restriction (based on psychomotor vigilance). Given the small sample size these results are preliminary and require replication.
- 21 November 2012
- Published by Wiley in Journal of Sleep Research
- Vol. 22 (2) , 160-165
Open AccessPER3 and ADORA2A polymorphisms impact neurobehavioral performance during sleep restriction
Summary: The objective of the study was to determine whether ADORA2A or PER3 polymorphisms contribute to individual responsivity to sleep restriction. Nineteen healthy adults (ages 18–39, 11 males, 8 females) underwent sleep restriction (SR) which consisted of seven nights of 3 h time in bed (TIB) (04:00–07:00). SR was preceded by seven in‐laboratory nights of 10 h TIB (21:00–07:00) and followed by three nights of 8 h TIB (23:00–07:00). Volunteers underwent psychomotor vigilance, objective alertness, and subjective sleepiness assessments throughout. Volunteers were genotyped for the PER3 VNTR polymorphism (PER34/4 n = 7; PER34/5 n = 10; PER35/5 n = 2) and the ADORA2A c.1083T>C polymorphism, (ADORA2AC/T n = 9; ADORA2AT/T n = 9; ADORA2AC/C n = 1) using polymerase chain reaction (PCR). Separate mixed‐model anovas were used to assess contributions of ADORA2A and PER3 polymorphisms. Results showed that PER34/4 and ADORA2AC/T individuals expressed greater behavioral resiliency to SR compared to PER4/5and ADORA2AT/T individuals. Our findings contrast with previously reported non‐significant effects for the PER3 polymorphism under a less challenging sleep restriction regimen (4 h TIB per night for five nights). We conclude that PER3 and ADORA2A polymorphisms become more behaviorally salient with increasing severity and/or duration of sleep restriction (based on psychomotor vigilance). Given the small sample size these results are preliminary and require replication.
- 1 August 2012
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 35 (8) , 1163-1172
Trait-Like Vulnerability to Total and Partial Sleep Loss
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.
- 1 August 2012
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 35 (8) , 1163-1172
Trait-Like Vulnerability to Total and Partial Sleep Loss
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.
- 29 February 2012
- Published by Elsevier in Drug Discovery Today: Disease Models
- Vol. 8 (4) , 139-146
Countermeasures to the neurocognitive deficits associated with sleep loss
- 29 February 2012
- Published by Elsevier in Drug Discovery Today: Disease Models
- Vol. 8 (4) , 139-146
Countermeasures to the neurocognitive deficits associated with sleep loss
- Open Access
- 1 March 2009
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 32 (3)
Banking Sleep: Realization of Benefits During Subsequent Sleep Restriction and Recovery
- 1 March 2009
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 32 (3)
Open AccessBanking Sleep: Realization of Benefits During Subsequent Sleep Restriction and Recovery
- 1 July 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 12 (20) , 2457-2471
Effects of Modafinil on Cognitive Performance and Alertness During Sleep Deprivation
The performance- and alertness-sustaining/restoring effects of modafinil during sleep deprivation in normal, healthy adults were reviewed. Results indicate that modafinil is efficacious for sustaining/restoring objective performance and alertness during sleep deprivation with few adverse effects. At appropriate dosages, modafinil restores performance and alertness to non-sleep deprived levels. Modafinil also impairs post-sleep deprivation recovery sleep, but from the few studies available addressing this issue, it is unclear whether these sleep impairments translate into post-sleep performance impairments. Further research is needed to determine whether modafinil restores performance on simple cognitive tasks only or whether modafinil additionally restores executive functions (e.g., abstract thought, critical reasoning, planning, decision-making, situational awareness, and effective judgment) which are critical in most modern operational settings. In addition, studies are needed to determine whether modafinil use during sleep deprivation is preferable to that of other available controlled stimulants (such as dextroamphetamine) or non-controlled stimulants (such as caffeine). Such studies would be comprised of direct, head-to-head comparisons among various stimulants across a range of dosages.
- 1 July 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 12 (20) , 2457-2471
Effects of Modafinil on Cognitive Performance and Alertness During Sleep Deprivation
The performance- and alertness-sustaining/restoring effects of modafinil during sleep deprivation in normal, healthy adults were reviewed. Results indicate that modafinil is efficacious for sustaining/restoring objective performance and alertness during sleep deprivation with few adverse effects. At appropriate dosages, modafinil restores performance and alertness to non-sleep deprived levels. Modafinil also impairs post-sleep deprivation recovery sleep, but from the few studies available addressing this issue, it is unclear whether these sleep impairments translate into post-sleep performance impairments. Further research is needed to determine whether modafinil restores performance on simple cognitive tasks only or whether modafinil additionally restores executive functions (e.g., abstract thought, critical reasoning, planning, decision-making, situational awareness, and effective judgment) which are critical in most modern operational settings. In addition, studies are needed to determine whether modafinil use during sleep deprivation is preferable to that of other available controlled stimulants (such as dextroamphetamine) or non-controlled stimulants (such as caffeine). Such studies would be comprised of direct, head-to-head comparisons among various stimulants across a range of dosages.
- Open Access
- 25 August 2005
- Published by Wiley in Journal of Sleep Research
- Vol. 14 (3) , 255-266
Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation
Summary: Stimulants may provide short‐term performance and alertness enhancement during sleep loss. Caffeine 600 mg, d‐amphetamine 20 mg, and modafinil 400 mg were compared during 85 h of total sleep deprivation to determine the extent to which the three agents restored performance on simple psychomotor tasks, objective alertness and tasks of executive functions. Forty‐eight healthy young adults remained awake for 85 h. Performance and alertness tests were administered bi‐hourly from 8:00 hours day 2 to 19:00 hours day 5. At 23:50 hours on day 4 (after 64 h awake), subjects ingested placebo, caffeine 600 mg, dextroamphetamine 20 mg, or modafinil 400 mg (n = 12 per group). Performance and alertness testing continued, and probe tasks of executive function were administered intermittently until the recovery sleep period (20:00 hours day 5 to 8:00 hours day 5). Bi‐hourly postrecovery sleep testing occurred from 10:00 hours to 16:00 hours day 6. All three agents improved psychomotor vigilance speed and objectively measured alertness relative to placebo. Drugs did not affect recovery sleep, and postrecovery sleep performance for all drug groups was at presleep deprivation levels. Effects on executive function tasks were mixed, with improvement on some tasks with caffeine and modafinil, and apparent decrements with dextroamphetamine on others. At the doses tested, caffeine, dextroamphetamine, and modafinil are equally effective for approximately 2–4 h in restoring simple psychomotor performance and objective alertness. The duration of these benefits vary in accordance with the different elimination rates of the drugs. Whether caffeine, dextroamphetamine, and modafinil differentially restore executive functions during sleep deprivation remains unclear.
- 25 August 2005
- Published by Wiley in Journal of Sleep Research
- Vol. 14 (3) , 255-266
Open AccessPerformance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation
Summary: Stimulants may provide short‐term performance and alertness enhancement during sleep loss. Caffeine 600 mg, d‐amphetamine 20 mg, and modafinil 400 mg were compared during 85 h of total sleep deprivation to determine the extent to which the three agents restored performance on simple psychomotor tasks, objective alertness and tasks of executive functions. Forty‐eight healthy young adults remained awake for 85 h. Performance and alertness tests were administered bi‐hourly from 8:00 hours day 2 to 19:00 hours day 5. At 23:50 hours on day 4 (after 64 h awake), subjects ingested placebo, caffeine 600 mg, dextroamphetamine 20 mg, or modafinil 400 mg (n = 12 per group). Performance and alertness testing continued, and probe tasks of executive function were administered intermittently until the recovery sleep period (20:00 hours day 5 to 8:00 hours day 5). Bi‐hourly postrecovery sleep testing occurred from 10:00 hours to 16:00 hours day 6. All three agents improved psychomotor vigilance speed and objectively measured alertness relative to placebo. Drugs did not affect recovery sleep, and postrecovery sleep performance for all drug groups was at presleep deprivation levels. Effects on executive function tasks were mixed, with improvement on some tasks with caffeine and modafinil, and apparent decrements with dextroamphetamine on others. At the doses tested, caffeine, dextroamphetamine, and modafinil are equally effective for approximately 2–4 h in restoring simple psychomotor performance and objective alertness. The duration of these benefits vary in accordance with the different elimination rates of the drugs. Whether caffeine, dextroamphetamine, and modafinil differentially restore executive functions during sleep deprivation remains unclear.
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 28 (1) , 93-103
Daytime Sleep and Performance Following a Zolpidem and Melatonin Cocktail
Pharmacologic enhancement of daytime sleep may help sustain optimal cognitive performance. At effective doses, Zolpidem induces sleep but also impairs performance. Combining melatonin with low-dose Zolpidem may promote daytime sleep without exacerbating performance impairments seen with high-dose Zolpidem alone. Following an 8-hour undisturbed nighttime sleep period, 80 subjects (50 men, 30 women) were administered oral Zolpidem 0, 5,10, or 20 mg at 10:00 am (n = 20 per group) and then oral melatonin 0 or 5 mg at 10:30 am (thus, n = 10 per drug combination) in a double-blind randomized fashion. Subjects napped from 10:00 am to 11:30 am, at which time they were awakened and cognitive tests administered (Restricted Reminding, Paired-Associates, and Psychomotor Vigilance). A second nap ensued from 12:45 pm to 4:00 pm, followed immediately by further testing. Melatonin 5 mg plus Zolpidem 0 mg enhanced daytime sleep (P < .05) with no memory or performance impairment (P > .05). Zolpidem 20 mg plus melatonin 0 mg also enhanced daytime sleep (albeit nonsignificantly), but memory and vigilance were impaired (P < .05). Melatonin's sleep-promoting effects were not evident until the second nap. No advantages to administering melatonin plus Zolpidem “cocktails” were evident. Unlike Zolpidem, melatonin 5 mg alone improved daytime sleep without impairing memory and vigilance. Functional coupling of sleep-inducing and memory-impairing effects may be specific to benzodiazepine-receptor agonists such as Zolpidem, suggesting potential advantages to using melatonin in the operational environment. That melatonin's sleep-promoting effects were delayed for several hours presents a practical consideration that may limit melatonin's usefulness when daytime sleep periods cannot be reliably anticipated or planned in advance.
- 1 January 2005
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 28 (1) , 93-103
Open AccessDaytime Sleep and Performance Following a Zolpidem and Melatonin Cocktail
Pharmacologic enhancement of daytime sleep may help sustain optimal cognitive performance. At effective doses, Zolpidem induces sleep but also impairs performance. Combining melatonin with low-dose Zolpidem may promote daytime sleep without exacerbating performance impairments seen with high-dose Zolpidem alone. Following an 8-hour undisturbed nighttime sleep period, 80 subjects (50 men, 30 women) were administered oral Zolpidem 0, 5,10, or 20 mg at 10:00 am (n = 20 per group) and then oral melatonin 0 or 5 mg at 10:30 am (thus, n = 10 per drug combination) in a double-blind randomized fashion. Subjects napped from 10:00 am to 11:30 am, at which time they were awakened and cognitive tests administered (Restricted Reminding, Paired-Associates, and Psychomotor Vigilance). A second nap ensued from 12:45 pm to 4:00 pm, followed immediately by further testing. Melatonin 5 mg plus Zolpidem 0 mg enhanced daytime sleep (P < .05) with no memory or performance impairment (P > .05). Zolpidem 20 mg plus melatonin 0 mg also enhanced daytime sleep (albeit nonsignificantly), but memory and vigilance were impaired (P < .05). Melatonin's sleep-promoting effects were not evident until the second nap. No advantages to administering melatonin plus Zolpidem “cocktails” were evident. Unlike Zolpidem, melatonin 5 mg alone improved daytime sleep without impairing memory and vigilance. Functional coupling of sleep-inducing and memory-impairing effects may be specific to benzodiazepine-receptor agonists such as Zolpidem, suggesting potential advantages to using melatonin in the operational environment. That melatonin's sleep-promoting effects were delayed for several hours presents a practical consideration that may limit melatonin's usefulness when daytime sleep periods cannot be reliably anticipated or planned in advance.